(NASDAQ: ANIP) Ani Pharmaceuticals's forecast annual revenue growth rate of 11.68% is forecast to beat the US Drug Manufacturers - Specialty & Generic industry's average forecast revenue growth rate of 10.62%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 13.54%.
Ani Pharmaceuticals's revenue in 2026 is $978,379,000.On average, 10 Wall Street analysts forecast ANIP's revenue for 2026 to be $25,818,675,648, with the lowest ANIP revenue forecast at $24,601,246,992, and the highest ANIP revenue forecast at $26,852,341,488. On average, 10 Wall Street analysts forecast ANIP's revenue for 2027 to be $28,712,940,000, with the lowest ANIP revenue forecast at $26,025,408,816, and the highest ANIP revenue forecast at $31,905,818,928.
In 2028, ANIP is forecast to generate $31,239,678,720 in revenue, with the lowest revenue forecast at $27,013,133,952 and the highest revenue forecast at $35,810,778,768.